-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Rubik's Cube Info
Author: Shi Bei
On December 20, Moderna announced the preliminary neutralizing antibody data of the mRNA new crown vaccine (elasomeran, mRNA-1273) at 50 µg and 100 µg doses against the Omicron variant
As mentioned before, Moderna is constantly advancing the booster vaccine to deal with the emerging mutants of concern (VOC)
The data disclosed on December 21 included sera from 20 booster vaccinators, including subjects vaccinated with mRNA-1273 (50µg and 100µg) booster, vaccinated with multivalent candidate vaccine mRNA-1273.
Before the booster shot, all groups had low levels of neutralizing antibodies to Omicron
Moderna also announced the safety and tolerability data of the Phase II/III study of a 100µg dose of mRNA-1273 (N=305) booster
Given the strength of mRNA-1273 and the propagation speed of Omicron variants, Moderna’s first line of defense against Omicron will be mRNA-1273 booster vaccination
On December 15th, Pfizer and BioNTech jointly announced that one month after receiving the booster vaccination (the third dose of BNT162b2 vaccine), the serum obtained from the vaccinee can neutralize the Omicron variant, and the neutralization level is the same as that of 2 doses.